MoonLake Immunotherapeutics — Third Quarter 2026 Earnings Summary

MoonLake Immunotherapeutics submitted a Biologics License Application to the FDA for sonelokimab to treat moderate-to-severe hidradenitis suppurativa in adults and adolescents. The company reported positive Week 16 results from the Phase 3 IZAR-1 trial in psoriatic arthritis, meeting all clinical endpoints for the 60 mg dose with induction, and completed enrollment in the Phase 3 IZAR-2 trial. Financial results for the third quarter of 2026 showed research and development expenses of $68.9 million, while the company ended the quarter with $498.5 million in cash and expects a runway to mid-2028. Upcoming milestones include an expected FDA decision on BLA acceptance by November 2026 and the commencement of enrollment for the Phase 3 NOVA trial in palmoplantar pustulosis in November 2026.